{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Rockwell Medical, Inc."},"Symbol":{"label":"Symbol","value":"RMTI"},"Address":{"label":"Address","value":"30142 S. WIXOM ROAD,SUITE 501, WIXOM, Michigan, 48393, United States"},"Phone":{"label":"Phone","value":"+1 248 960-9009"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The company's drug products are Triferic. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. The company operates in one segment of the hemodialysis market which involves the exports, manufacture, sale, and distribution of hemodialysis products. Key revenue is generated from the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.rockwellmed.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Marc Hoffman","title":"Chief Medical Officer"},{"name":"Mark Strobeck","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}